IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQVIA NYSE: IQV reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing accelerating organic growth across its Commercial Solutions and R&D Solutions businesses, increased demand tied to artificial intelligence offerings and continued strength in forward-looking clinical development metrics.
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call Transcript
IQVIA tops on Q1 EPS and revenues on strong Commercial Solutions growth, lifts its 2026 EPS outlook and keeps the revenue & EBITDA guidance steady.
IQVIA Holdings (IQV) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.83 per share. This compares to earnings of $2.7 per share a year ago.
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA's AI push with NVIDIA, strategic deals and buybacks drive growth, but weakening liquidity raises concerns over near-term financial flexibility.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Broyhill Asset Management LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 15.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,010 shares of the medical research company's stock after buying an additional 3,560 shares during the